Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
SynKinase
IPI-145
CHF 0.00
In stock
SYN-1175-M0011 mgCHF 149.00
SYN-1175-M0055 mgCHF 234.00
SYN-1175-M01010 mgCHF 390.00
SYN-1175-M05050 mgCHF 1'320.00
SYN-1175-M100100 mgINQ
| Product Details | |
|---|---|
| Synonyms | IPI 145 |
| Product Type | Chemical |
| Properties | |
| Formula | C22H17ClN6O |
| MW | 416.9 |
| CAS | 1201438-56-3 |
| Purity Chemicals | ≥95% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO. Slightly soluble (<1mg/ml) in ethanol. |
| Declaration | Manufactured by SynKinase. |
| Other Product Data |
Target: mTOR - PI3K | Kinase Group: Atypical (PIKK) | Substrate: Serine-Threonine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
| InChi Key | SJVQHLPISAIATJ-ZDUSSCGKSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
IPI-145 is a potent, oral inhibitor of Class I phosphoinositide-3-kinase (PI3K)-δ and PI3K-γ (IC(50) of 243 pM and 50nM), and is clinically active in patients with advanced hematological malignancies.
Product References
- PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models: D.G. Winkler, et al.; Chem. Biol. 20, 1364 (2013)
- Novel phosphoinositide 3-kinase δ,γ inhibitor: potent anti-inflammatory effects and joint protection in models of rheumatoid arthritis: D.L. Boyle, et al.; J. Pharmacol. Exp. Ther. 348, 271 (2014)
- IPI-145 shows promise in CLL patients: Cancer Discov. 4, 136 (2014)
Related Products
